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Abstract
Background: Nasal continuous positive airway pressure (CPAP) applies positive end-expiratory pressure (PEEP) and
has been shown to reduce the need for intubation and invasive mechanical ventilation in very low birth weight
infants with respiratory distress syndrome. However, CPAP failure rates of 50% are reported in large randomized
controlled trials. A possible explanation for these failure rates is the application of insufficient low levels of PEEP
during nasal CPAP treatment to maintain adequate functional residual capacity shortly after birth. The optimum
PEEP level to treat symptoms of respiratory distress in very low birth weight infants has not been assessed in
clinical studies. The aim of the study is to compare two different PEEP levels during nasal CPAP treatment in
preterm infants.
Methods: In this randomized multicenter trial, 216 preterm infants born at 26 + 0–29 + 6 gestational weeks will be
allocated to receive a higher (6–8 cmH2O) or a lower (3–5 cmH2O) PEEP during neonatal resuscitation and the first
120 h of life. The PEEP level within each group will be titrated throughout the intervention based on the FiO2
(fraction of inspired oxygen concentration) requirements to keep oxygenation within the target range. The primary
outcome is defined as the need for intubation and mechanical ventilation for > 1 h or being not ventilated but
reaching one of the two pre-defined CPAP failure criteria (FiO2 > 0.5 for > 1 h or pCO2 ≥ 70 mmHg in two
consecutive blood gas analyses at least 2 h apart).
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Discussion: Based on available data from the literature, the optimum level of PEEP that most effectively treats
respiratory distress syndrome in preterm infants is unknown, since the majority of large clinical trials applied a wide
range of PEEP levels (4–8 cmH2O). The rationale for our study hypothesis is that the early application of a higher
PEEP level will more effectively counteract the collapsing properties of the immature and surfactant-deficient lungs
and that the level of inspired oxygen may serve as a surrogate marker to guide PEEP titration. Finding the optimum
noninvasive continuous distending pressure during early nasal CPAP is required to improve CPAP efficacy and as a
consequence to reduce the exposure to ventilator-induced lung injury and the incidence of chronic lung disease in
this vulnerable population of very preterm infants.
Trial registration: drks.de DRKS00019940. Registered on March 13, 2020
Keywords: Nasal CPAP, RDS, Preterm infants, PEEP
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Introduction
Background and rationale {6a}
Very low birth weight infants (VLBWI) with surfactant
deficient lungs frequently develop respiratory distress
syndrome (RDS) with the need of early respiratory
support in the delivery room and during the active
phase of RDS (i.e., first 5 days of life) [1]. The use of
nasal CPAP to avoid intubation and the consecutive
detrimental effects of invasive mechanical ventilation to
the immature lungs has been shown to reduce the rate
of bronchopulmonary dysplasia (BPD) and death in
meta-analyses [2]. The diagnosis of BPD is associated
with lifelong impaired lung function and negatively af-
fects the neurodevelopmental outcome in this high risk
group of infants [3]. Nasal CPAP in the delivery room is
now the recommended primary respiratory support in
preterm infants with RDS. Results of large randomized
controlled trials comparing early nasal CPAP versus pri-
mary intubation found that approximately 46.0–51.2% of
infants can be saved from intubation with this approach
[4, 5]. However, almost half of the infants in the large
CPAP trials failed on CPAP, which ultimately resulted in
exposure to some degree of invasive mechanical ventila-
tion and may explain limited effects on the reduction of
the incidence of BPD [1, 6, 7]. Application of early nasal
CPAP aims to recruit the lungs and maintain functional
residual capacity (FRC). The degree of lung recruitment
is influenced by the level of PEEP applied to the imma-
ture lung [8]. Expert panels from international societies
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currently recommend a PEEP level of 5–6 cmH2O [4, 9].
However, as the authors state, evidence for these recom-
mendations is very limited. No clinical studies specific-
ally assessed the effect of different PEEP levels during
the active phase of RDS in preterm infants on outcomes
such as the need for invasive mechanical ventilation and
other neonatal morbidities (i.e., BPD). Results of a sec-
ondary analysis from a cohort study in 34 international
centers that participated in a nasal intermittent positive
pressure ventilation trial indicate a large variation of
PEEP levels used in clinical practice during neonatal re-
suscitation and the first 28 days of life (i.e., 3–9 cmH2O)
[10]. Only one clinical trial with a small sample size, in-
cluding preterm infants beyond the active phase of RDS,
randomized subjects to receive a higher or a lower level
of PEEP after extubation (4–6 cmH2O versus 7–9
cmH2O) and found a significantly lower rate of reintuba-
tion in the higher PEEP group [11]. Results from animal
studies further suggest that using higher PEEP levels (8–
12 cmH2O) improves gas exchange and avoids lung col-
lapse when compared to lower levels of PEEP [12, 13].
The optimum level of PEEP during nasal CPAP that ef-
fectively maintains FRC and avoids mechanical ventila-
tion in preterm infants with RDS is unknown and
remains to be determined.
The proposed randomized controlled trial was
designed and powered to compare the effect of two
different PEEP levels during nasal CPAP (6–8 cmH2O
versus 3–5 cmH2O) in preterm infants in the first 120 h
of life on the need for intubation and the incidence of
pre-defined CPAP failure criteria.
Objectives {7}
The primary hypothesis of this study is that the use of a
higher PEEP range in preterm infants born at 26 + 0–
29 + 6 weeks gestational age (GA) receiving prophylactic
nasal CPAP support after birth reduces the incidence of
intubation and/or meeting predefined CPAP failure
criteria within the first 120 h of life when compared to
the application of a lower PEEP range.
Trial design {8}
This will be an unblinded multicenter randomized
controlled parallel group comparison of two different
PEEP ranges during nasal CPAP support in the first
120 h of life.
Methods: participants, interventions, and
outcomes
Study setting {9}
Participating centers
The below listed centers and site investigators will be
actively recruiting for the trial:
Department of General Pediatrics and Neonatology,
Justus-Liebig-University of Giessen; Harald Ehrhardt,
Markus Waitz.
Department of Neonatology, University of Tuebingen;
Axel Franz.
Division of Neonatology, University of Frankfurt; Rolf
Schloesser, Ulrich Rochwalsky.
Department of Pediatrics and Neonatology, University
Children’s Hospital of Saarland; Sascha Meyer, Michael
Zemlin.
Division of Pediatric Pulmonology, Allergology and
Neonatology, Hannover Medical School; Bettina
Bohnhorst, Corinna Peter.
Department of Neonatology and Pediatric Intensive
Care Medicine, Children’s Hospital, Cologne; Marc
Hoppenz, Thomas Pabst.
Eligibility criteria {10}
Inclusion criteria
 GA at birth 26 + 0/7 to 29 + 6/7 weeks
Exclusion criteria
 Severe congenital anomalies affecting breathing
control (cerebral anomalies, chromosomal
anomalies, prenatally diagnosed intracranial
hemorrhage) or gas exchange (pulmonary hypoplasia
due to congenital diaphragmatic hernia or oligo/
anhydramnios present at < 22 weeks GA or other
pulmonary or intrathoracic malformations, etc.) or
hemodynamics (cyanotic heart disease, ductal
dependent systemic perfusion, or similar)
 Decision not to provide full life support/decision for
palliative care only before study entry
 Parents not able to understand the study due to
language barriers
Who will take informed consent? {26a}
All pregnant women who are admitted to the local
prenatal/maternity wards with threatening preterm
delivery before 29 + 6/7 weeks should be approached.
Both parents will be asked for consent for their baby to
participate in the study given that it will be delivered
between 26 + 0 and 29 + 6 weeks of gestation. Informed
consent will be taken by good clinical practice (GCP)
qualified staff members.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
To date, no sampling of biological material is planned
during the study.
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Interventions
Explanation for the choice of comparators {6b}
Since the optimum level of PEEP to treat RDS is
unknown, we decided to choose the levels of PEEP
within the reported PEEP levels used in clinical practice
from large surveillance data (3–9 cmH2O) and within
the limits of current treatment guidelines [4, 9, 10]. To
allow for effective discrimination between the two
treatment groups, we decided that the difference of the
applied level of PEEP in the delivery room must be
exactly 3 cmH2O. At last, the choice of the defined
PEEP levels yielded the highest agreement in the pre-
study meetings of all participating centers.
Intervention description {11a}
Study intervention
The study intervention is the application of early nasal
CPAP/nasal intermittent positive pressure ventilation
(NIPPV) with higher PEEP range (6–8 cmH2O,
intervention group) compared to a lower PEEP range
(3–5 cmH2O, control group) in the first 120 h of life.
Interventional period
The intervention starts immediately after birth with the
first application of nasal CPAP/NIPPV in the delivery
room. The study intervention ends at a postnatal age of
120 h. Randomized subjects will receive nasal CPAP/
NIPPV immediately after birth using a short
nasopharyngeal tube, face mask, or binasal prongs
(center specific). The PEEP level will be set within the
allocated PEEP range: PEEPlow (3–5 cmH2O) or
PEEPhigh (6–8 cmH2O). During resuscitation, the initial
PEEP setting in the intervention group must be set 3
cmH2O higher than in the control group and will be
determined by center guideline prior to study start. The
initial PEEP will be maintained during the delivery room
management and will not be adjusted. Application of
PEEP in the delivery room will be provided by a T-Piece
resuscitator or a conventional ventilator. The use of a
self or flow-inflating bag is not permitted for initial re-
spiratory support. Subjects will be further resuscitated
according to the European Consensus Guidelines [4].
Sustained inflation maneuvers can be applied according
to local policies for initial stabilization. Primary nasal
NIPPV (synchronized or not) can be used in the delivery
room. After admission to the neonatal intensive care
unit, the PEEP level will be adjusted according to the
level of inspired oxygen required to meet the center-
specific study SpO2 target range within the maximum
range of 85–95% throughout the interventional period
using the following PEEP titration protocol: (PEEP ad-
justments should be made on a half-hourly basis to allow
the assessment of effects).
Prior to study initiation, we strongly recommend local
guidelines for intubation and mechanical ventilation be
defined, as well as the indication criteria for surfactant
administration that have to be applied equally within
both PEEP groups. Suggested intubation criteria within
the study are:
FiO2 ≥ 0.5 for > 1 h and/or pCO2 ≥ 70mmHg in two
consecutive blood gas analysis > 2 h apart after the appli-
cation of a maximum of 2 surfactant doses (either
INSURE (intubate surfactant extubate) or less invasive,
i.e., LISA).
If a study subject requires intubation, decisions on the
mode of invasive ventilation, weaning strategies, and
extubation are at the discretion of the responsible med-
ical team of the study site with settings and modes iden-
tical for both treatment groups. After extubation, the
PEEP will be set and adjusted according to the initially
assigned PEEP range during nasal CPAP/NIPPV. After
the study intervention period, the medical team at each
study site will decide on the further mode of respiratory
support and weaning strategies.
Continuous documentation of the study intervention
In both treatment groups, FiO2, set PEEP levels, and
pressures during CPAP and NIPPV (mean airway pres-
sure, peak inspiratory pressure, inspiratory time) will be
recorded every hour throughout the interventional
period on a worksheet and has to be signed by a study
physician. All data will be transferred from hardcopy to
electronic CRF files and are stored within the database
of the center for pediatric clinical studies (CPCS), Uni-
versity of Tuebingen. This database fulfills all GCP and
FDA CFR part 11 requirements. After termination of the
study, all datasets are backed up within a locked area at
the Justus-Liebig-University of Giessen and at the
Eberhard-Karls-University of Tuebingen for at least 10
years after the end of the study.
Criteria for discontinuing or modifying allocated
interventions {11b}
Individual preterm end of study intervention
For the individual patient Treatment may be termi-
nated for safety concerns by the attending physician to-
gether with the local principal investigator or according
to the wish of the patient’s parents or legal representa-
tives at any time. The reasons for premature termination
of the study intervention have to be documented in the
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study database. These patients will be maintained in the
study, study visits have to be done as planned, and their
outcome will be included in the intention-to-treat
analysis.
Preterm end of study
For a study center A study center not following the
protocol or failing to recruit patients may be closed pre-
maturely. All infants already recruited at that center will
be maintained in the study, study visits have to be done
as planned, and their outcome will be included in the
intention-to-treat analysis.
For the whole study For safety: all potential complica-
tions related to the intervention occurring during the
care of an infant enrolled in this trial have to be reported
immediately to the coordinating investigator according
to ICH-GCP guidelines and national and European
regulations. Furthermore, information on all
prematurity-associated complications is collected in the
study database. These will include safety reports after 50,
100, and 150 completely documented patients to the
data monitoring committee (DMC), who will continu-
ously keep track of the incidence of such events in both
study groups. The trial will be stopped by the coordinat-
ing investigator on the advice of the DMC, if the risk-
benefit ratio of the study intervention (i.e., application of
higher PEEP ranges) is significantly changed based on
new published data becoming available. The trial will
also be stopped temporarily or permanently in case that
safety outcomes (i.e., mortality or major diseases of pre-
maturity) occur more frequently in the treatment group
or if complications directly related to the study interven-
tion (e.g., adverse events directly attributable to device
failures) require a change in the risk-benefit assessment.
Strategies to improve adherence to interventions {11c}
Local principal investigators and team members are re-
quired to participate in a pre-study meeting where de-
tails of study protocol, data collection, the application,
and adjustments of PEEP will be discussed. All partici-
pating centers will receive detailed written instructions.
In cases of uncertainty, it will be possible to contact the
Center for Pediatric Clinical Studies (CPCS, University
of Tuebingen) at any time.
Relevant concomitant care permitted or prohibited
during the trial {11d}
Management with alternative noninvasive respiratory
support (i.e., NIPPV)
NIPPV is frequently used as primary mode of noninva-
sive ventilation in the delivery room and the first days of
life. Because the settings during NIPPV affect the applied
mean airway pressure and gas exchange, NIPPV settings
and weaning during the study intervention must be
equally used in terms of inspiratory times, respiratory
rate, and peak inspiratory pressures, which will be moni-
tored and documented during the study intervention.
We strongly recommend a center-specific protocol for
the use of NIPPV prior to study initiation.
Caffeine therapy
Randomized infants will receive a loading dose of caf-
feine citrate of (10)–20 mg/kg and a maintenance dose
of (5)–10mg/kg/days. Up to 20mg/kg/days is permitted
to prevent intubation due to apnea of prematurity. Be-
cause the optimal dose of caffeine has not yet been
established, exact dosing will be left to the standards of
the participating centers—but centers will need to have
a written dosing scheme. Furthermore, caffeine treat-
ment will be monitored throughout the study to detect
any bias in caffeine use early.
Provisions for post-trial care {30}
Patients that are enrolled into the study are covered by
patient insurance (HDI Global SE).
Outcomes {12}
The primary outcome is meeting one of the following
treatment failure criteria within the first 120 h after
birth:
1. Need for intubation and invasive mechanical
ventilation for > 1 h
or
2. FiO2 ≥ 50% for > 1 h after NICU admission
or
3. pCO2 ≥ 70 mmHg in two consecutive blood gas
analyses > 2 h apart
Secondary outcomes are:
1. Rates of invasive or less invasive surfactant
administration
2. Cumulative dose of surfactant in mg/kg birth
weight
3. Rate of intubation and invasive mechanical
ventilation within the first 120 h after birth
4. Duration of invasive mechanical ventilation within
the first 120 h of life (cumulative hours)
5. Duration of invasive mechanical ventilation until
PMA36 or death (cumulative hours)
6. Duration of any respiratory support until PMA36 or
death (cumulative days)
7. Rate and severity distribution of BPD
8. Rate of discharge with supplemental oxygen
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9. Rates of postnatal systemic dexamethasone and/or
hydrocortisone intended for chronic lung disease
10. Rate of inhaled steroids
11. Need for inotropes/vasopressors within the first
120 h of life
12. Need for steroids for treatment of arterial
hypotension within the first 120 h of life
13. Mean FiO2 requirements within the first 120 h of
life
14. Mean airway pressure within the first 120 h after
birth
Further outcomes are:
1. Bayley Scales of Infant Development (3rd) Edition
at 24 months corrected age
2. Visual assessment at 24 months corrected age
3. Hearing assessment at 24 months corrected age
4. GMFCS-Score at 24 months corrected age
5. Wechsler preschool and primary scale of
intelligence (WPPSI-III) at 60 months corrected age
6. Lung function at 60 months corrected age
7. MRI of the lung and brain at 60 months
Participant timeline {13}
Study procedures, examination methods, and outcome
assessment
The description of the study procedures and examina-
tions are shown in Fig. 1. A summary of important out-
comes and time points of assessment are shown in
Table 1. A detailed description of the study process for
the individual patient is summarized in Fig. 2.
Sample size {14}
Based on a pre-study survey among participating centers
and the results of the AMV study [14], we expect 50%
primary endpoints within the control group (lower PEEP
level). The intervention will be regarded as being suc-
cessful if it lowers the rate of the primary endpoints to
30%. This follows the expectations within similar studies
[15]. To lower the rate of primary endpoints from 50 to
30% and to confirm this via Cochran-Mantel-Haenszel
test (level of significance = 0.05, power = 80%), a sample
size of 103 patients per group will be needed. To ac-
count for 5% drop outs, an overall sample size of 216 pa-
tients have to be recruited and treated within the study.
Recruitment {15}
Recruitment and study duration
Patients will be recruited in 6 German tertiary care neo-
natal centers. Results of a systematic surveillance proto-
col prior to study start yielded a number of 240 eligible
preterm infants meeting the inclusion criteria annually
in all participating centers. Based on the assumption that
approximately 50% of eligible infants will be included in
the study, the recruitment period is expected to be 27
months. All preterm infants who are born at the partici-
pating institutions with a gestational age at birth of 26 +
0/7 to 29 + 6/7 weeks have to be screened for the study.
Each screened patient is given a patient screening num-
ber (PSN) in consecutive order according to the screen-
ing log in the investigator site file (ISF). This number is
the overall identifier of the pseudonymized patient
throughout the study. For every screened patient, a
screening form has to be filled in the electronic case re-
port form (eCRF). This enables the documentation of
non-biased recruitment. The screening eCRF form will
document presence and absence of inclusion and exclu-
sion criteria, whether the parents had been approached
and whether informed consent was given, but will not
document any patient identifiers. Outborn infants will
not be screened as study treatment has to start immedi-
ately after birth. Patients can only be enrolled into the
study if informed written consent was given by both par-
ents/guardians (by the only parent/guardian in case of
single-parent/guardian families) before birth. In case
parents are less than 18 years of age, the relevant legal
guardian(s) of the child has/have to sign the informed
Fig. 1 Overview about the study procedures and examinations. IC, informed consent; CUS, cerebral ultrasound; MRI, magnetic resonance
imaging; PMA, postmenstrual age
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consent. Following multiple birth, parents are asked
whether the infants could be randomized separately. If
parents wish randomization to one study arm, the sec-
ond child is treated like the randomized child, but not
recruited to the study. The parental wish is documented
on the informed consent form.
Assignment of interventions: allocation
Sequence generation {16a}
Randomization and allocation concealment
Infants will be randomly assigned in a 1:1 ratio with
variable block sizes. Randomization lists will be stratified
by center and gestational age (26 + 0–27 + 6 and 28 + 0–
Table 1 Time points of interventions and outcome assessment of outcomes during the study
Points of action Screening Baseline Visits End of inpatient
study
Follow-up End of
study
Visit 1 2 3 4 5 6 7 8 9
Time point/age Prior
birth
0 h 120
h
Day
7
PMA
36
Discharge 24months corrected
age
60 months of
age
Inclusion criteria ●
Exclusion criteria ●
Informed consent ●
Neonatal and maternal characteristics
Data ●
Study intervention/ventilation
Start ●
End ●
PEEP data ●
Surfactant treatment ●
Ventilation data ● ● ●
Safety
Serious adverse
events
Continuous reporting until discharge
Outcome assessment
BPD ●
Death ● ●
ROP ●
NEC ●
FIP ●
PDA ●
Nosocomial
infections
●
Brain injury (CUS) ● ●
Feeding data ●
Inotropes ●
Postnatal steroids ●
Bayley III/GMFCS ●
Visual and hearing ●
Lung function ●
WPPSI-III ●
Lung/brain MRI ●
Parental
questionnaire
Every 3 months after discharge
BPD bronchopulmonary dysplasia, CUS cerebral ultrasound, FIP focal intestinal perforation, GMFCS gross motor function classification scale, MRI magnetic
resonance imaging, NEC necrotizing enterocolitis, PDA persistent ductus arteriosus, PMA postmenstrual age, ROP retinopathy of prematurity
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Fig. 2 Study process for the individual patient
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29 + 6 weeks). Sequentially numbered, sealed, opaque en-
velopes indicating the study group will be prepared.
Provision of randomization envelopes will be done by an
independent institution not involved in patient
recruitment.
Concealment mechanism {16b}
Please see the “Sequence generation {16a}” section.
Implementation {16c}
Please see the “Sequence generation {16a}”section.
Assignment of interventions: blinding
Who will be blinded {17a}
Blinding of doctors, nurses, and parents for the interven-
tion is not possible in this study.
Procedure for unblinding if needed {17b}
Please see the “Who will be blinded {17a}” section.
Data collection and management
Data management plan, quality assurance, and
monitoring
A data management plan will be written describing the
whole flow of the study data. Documentation of study
data will be done by the local principal investigator via
eCRF within a web-based study database. Source data
will remain within the study sites. Quality and correct-
ness of the study data will be ascertained by GCP-
conform monitoring of the study. Monitoring will be
done on a risk-adapted basis and will include remote
and on-site monitoring of the data by trained monitors.
Plans for assessment and collection of outcomes {18a}
Please see the “Study procedures, examination methods,
and outcome assessment” section.
Plans to promote participant retention and complete
follow-up {18b}
Data management {19}
Please see the “Data management plan, quality assur-
ance, and monitoring” section.
Confidentiality {27}
Plans for collection, laboratory evaluation, and
storage of biological specimens for genetic or
molecular analysis in this trial/future use {33} To
date, no sampling of biological material is planned dur-
ing the study.
Statistical methods
Statistical analysis {20a}
The following analysis populations are defined within
this study:
1. Intention to treat population
Consists of all patients included into the study of
whom written parental consent was obtained and
not withdrawn.
2. Safety population
The safety population is identical to the intention to
treat population and consists also of all patients
included into the study of whom written parental
consent was obtained and not withdrawn.
3. Per protocol population
Patients fulfilling at least one of the following
criteria will be excluded from the per protocol-
population:
 PEEP level is not documented or not between 3
and 5 cmH2O—if the infant is in the low PEEP
group—or 6–8 cmH2O—if it is randomized in
the high PEEP group—for more than 10% of
time during the intervention period.
 Intubation within the first 10 min after birth and
invasive mechanical ventilation for more than
1 h.
The analysis of the primary endpoint will be done by
Cochran-Mantel-Haenszel test stratified for treatment
groups. The primary endpoint will be re-evaluated by
Cochran-Mantel-Haenszel test adjusted for gestational
age group (26 + 0–27 + 6 versus 28 + 0–29 + 6 weeks)
and center. If the final number of centers does not allow
adjustment for single centers, centers will be grouped.
The grouping of centers will be justified within the stat-
istical analysis plan. All secondary endpoints will be
compared by Cochran-Mantel-Haenszel test or Student’s
t test. In case of non-normally distributed data, Student’s
t test will be replaced by Wilcoxon-Mann-Whitney test.
The distribution of severity of BPD will be compared
between the treatment groups by generalized logit
model. Clinical and demographic characteristics of ma-
ternal and neonatal data will be described by mean and
standard deviation, median, quartiles and minimum/
maximum or rate and percentage. The analysis of the
follow-up endpoints will be specified in an amendment
to the study protocol before start of the 2- and 5-year
follow-up. In case of more than 10% missing values con-
cerning the primary endpoint, a worst case/best case
analysis for this endpoint will be performed in the
intention to treat population as sensitivity analyses and
results will be included into the final report. No sensitiv-
ity analyses will be done for secondary or further rele-
vant endpoints. In case of more than 20% missing values
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concerning one of the endpoints until PMA36, this end-
point will only be tabulated but no statistical test will be
performed due to risk of biased data.
All analyses will be predefined in a statistical analysis
plan written before end of study and completion of data
monitoring. Only the analysis of the primary outcome
variable in the intention-to-treat population will be con-
sidered confirmatory on a level of significance of 0.05.
All other analyses including the analysis of the primary
outcome variable in the per protocol population and all
analyses concerning secondary endpoints will be consid-
ered exploratory only.
Interim analyses {21b}
Not planned
Methods for additional analyses (e.g., subgroup analyses)
{20b}
There are no subgroup analyses predefined within the
study protocol. If appropriate, they will be defined within
the statistical analyses plan.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Please see the “Statistical analysis {20a}” section.
Plans to give access to the full protocol, participant level-
data, and statistical code {31c}
Access to the full study protocol and the final statistical
analysis plan will be given upon request. There is no
plan to give access to participant-level data for data pro-
tection reasons.
Oversight and monitoring
Composition of the coordinating center and trial steering
committee {5d}
Please see the “Composition of the data monitoring
committee, its role and reporting structure {21a}”
section.
Composition of the data monitoring committee, its role
and reporting structure {21a}
The DMC is represented by two neonatologists inde-
pendent from the sponsor or competing interests. The
DMC will be contacted by the two coordinating investi-
gators (Harald Ehrhardt and Markus Waitz) based on
their expertise (being at least principal investigators in
clinical trials for more than 5 years in the past and ex-
perts in the field of neonatology). Details (name and
contact information) of the composition of the DMC are
provided in the study protocol or upon request. Safety
aspects will be documented continuously throughout the
study including the categories expected serious adverse
events (eSAE) and unexpected serious adverse events
(uSAE) events and will be reported within safety reports
to the DMC. Safety analyses will be done after 50, 100,
and 150 included patients have reached PMA 36 weeks.
Reports of these data will be sent to the DMC members
by the responsible biometrician (CPCS, University of
Tuebingen). Based on the reported data, the DMC will
provide recommendations on continuation of the trial
and will report its decision to the coordinating
investigators.
Adverse event reporting and harms {22}
The following expected serious (eSAE) and unexpected
serious (uSAE) adverse events known to occur in this
population of very preterm infants will be reported to
the DMC as rates and percent, stratified for treatment
group.
eSAE:
 Death before discharge
 Necrotizing enterocolitis stage ≥ 2 or need for
surgery
 Focal intestinal perforation
 Any intraventricular hemorrhage
 Any intraventricular hemorrhage ≥ 3°
 Periventricular leucomalacia
 Any persistent ductus arteriosus requiring treatment
(medical/surgical)
 Any retinopathy of prematurity requiring treatment
 Rate of air leak syndromes (i.e., pneumothorax,
pulmonary interstitial emphysema,
pneumoperitoneum, pneumopericardium,
pneumomediastinum)
 Rate of any air leak syndrome associated with any
intraventricular hemorrhage
All other adverse events meeting the following criteria
of seriousness will be considered unexpected serious ad-
verse events and must be documented in the AE-from of
the eCRF.
uSAE (any adverse event that resulted in any of the
following):
 Death
 Serious deterioration in the health of the subject
that resulted in any of the following:
– Life-threatening illness or injury,
– Permanent impairment of a body structure or a
body function,
– Medical or surgical intervention to prevent life-
threatening illness or injury or permanent impair-
ment to a body structure or a body function.
To ensure that there is no higher risk of deaths caused
by the intervention, this will be evaluated with the help
of 95% confidence limits that will be presented for both
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treatment groups. A DMC manual will describe the de-
tails of the safety analysis and has to be approved by all
DMC members before preparing the first DMC report.
Frequency and plans for auditing trial conduct {23}
Monitoring for this study is provided by the Center for
Pediatric Clinical Studies (CPCS) of the University
Hospital Tuebingen. Central monitoring of the eCRF
will also be provided by the CPCS, certified by ISO9001.
Monitoring is employed primarily for the subjects’ safety,
as well as for quality assurance of medical procedures.
The centers will be visited by the monitor on a regular
basis. In accordance with the laws on data protection,
the investigator’s files, data collection forms, and original
documents have to be made available to the monitor.
The investigators will discuss the course of the study
with the monitor in an appropriate manner. Trial insti-
tutions, facilities, laboratories, and all data (including
raw data and eCRFs) must always be available for in-
spection by an authority.
Plans for communicating important protocol
amendments to relevant parties (e.g., trial participants,
ethical committees) {25}
Any additions and changes made to the protocol have to
be submitted to the responsible Ethics Committees for
review. Changes to protocol procedures (amendments)
require a specification of reasons and must be signed by
an authorized person for the respective protocol; the
amendments are then considered part of the protocol.
Substantial changes, in particular with regard to patients’
health interests, require a new decision from the appro-
priate Ethics Committees.
Dissemination plans {31a}
The final report for the study will be compiled by the
coordinating investigators within a period of 360 days
upon completion of the study and forwarded to the eth-
ics committees. Furthermore, the coordinating investiga-
tors will submit the final report for publication as soon
as possible.
Consent for publication
Not applicable
Discussion
Nasal CPAP application with selective surfactant admin-
istration is currently the primary and recommended re-
spiratory support in very low birth weight infants with
developing or active RDS [1, 4]. CPAP has been proven
to be at least as effective as primary intubation in the
delivery room with regard to the outcome of BPD and
significantly reduced the need for invasive mechanical
ventilation in large randomized controlled trials [1, 6, 7].
However, reported CPAP failure rates in these trials are
still high (46.0–51.2%) and CPAP failure was ultimately
linked with the exposure to mechanical ventilation, an
intervention clearly associated with the diagnosis of BPD
[5, 14, 16]. PEEP levels used in these trials ranged from
4 to 8 cmH2O. The evidence for the decision to apply
these specific PEEP levels of 4–8 cmH2O in very imma-
ture preterm infants is low but considered to be safe.
From a pathophysiological perspective, early application
of PEEP to the surfactant deficient lungs counteracts the
collapsing properties, maintains FRC, and supports lung
liquid clearance immediately after birth [17]. In an at-
tempt to accelerate lung liquid clearance, sustained in-
creases of continuous positive airway pressure (i.e.,
sustained lung inflation maneuvers (SLI)) have been pro-
posed to effectively recruit gas exchange units after birth
[18]. While this SLI strategy has been shown to reduce
the need for intubation within the first 72 h of life in
VLBWI, the results of the SAIL trial showed no differ-
ence in the rate of BPD, but an increased mortality in
the SLI group discouraging the use of this aggressive re-
cruitment technique [18, 19]. Effective lung liquid clear-
ance is necessary to allow gas exchange, but the
approach of SLI does not take into account the fact that
interstitial liquid tends to re-accumulate in the pulmon-
ary tissue over a longer period of time [20]. In addition,
RDS caused by primary surfactant deficiency of the pre-
mature lungs predisposes atelectasis and consecutive im-
paired gas exchange. It is considered a longer lasting
dynamic disease process and therefore may require pro-
longed and sufficient PEEP support [21]. Early surfactant
treatment, in the recent years predominantly adminis-
tered via less invasive application procedures or the
INSURE technique in the neonatal population, further
reduced the need of invasive ventilation, but unfortu-
nately did not yield the desired reduction in the inci-
dence of BPD in multicenter studies [7, 14]. Stepwise
recruitment strategies (IN-REC-SUR-E – Intubate Re-
cruit Surfactant Extubate) using invasive high frequency
oscillatory ventilation, where FiO2 serves as surrogate
marker of effective lung inflation, combined with surfac-
tant administration are currently under investigation and
have been shown to reduce oxygen requirements and
the incidence of BPD in one randomized controlled trial
and retrospective studies [15, 22, 23]. SLI maneuvers
and the INRECSURE procedures aim to apply higher
pressures over a short period of time indicating that the
immature preterm lung may require higher continuous
distending pressures than expected in the past. However,
clinical trials assessing the application of early, pro-
longed and higher levels of non-invasive PEEP to avoid
collapse of the neonatal lung during nasal CPAP are not
available but may be an alternative or adjunctant to the
abovementioned ventilation and treatment strategies.
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The hypothesis that early application of “higher” PEEP
levels could be beneficial is supported by animal data
where higher PEEP levels (8–12 cmH2O) were more ef-
fective than lower levels in terms of gas exchange [12,
13]. More recently, a dynamic increase of PEEP in pre-
term lambs (up to 14–20 cmH2O for 3 min) improved
response to surfactant treatment and created a more
uniform lung aeration, compared to positive pressure
ventilation or SLI maneuvers [24]. Further evidence that
higher pressure levels may decrease the need for invasive
mechanical ventilation derives from studies using NIPPV
as a mode of non-invasive respiratory support. This ven-
tilation strategy augments CPAP by superimposing posi-
tive pressure inflation at different respiratory rates,
imitating time-cycled pressure-controlled ventilation.
Results of the actual meta-analyses showed a reduction
of the need for intubation and reintubation compared to
nasal CPAP when NIPPV was used as primary mode of
ventilation or post extubation [25, 26]. It is unclear how
NIPPV mediates its clinical benefits, but one possible ex-
planation could be the increase in mean airway pressure
during NIPPV [27].
Concerns that may have discouraged the further as-
sessment of higher levels of PEEP in the neonatal popu-
lation might derive from results of the COIN trial where
infants in the CPAP group had a higher rate of pneu-
mothoraces with the use of a PEEP of 8 cmH2O [1]. This
association, however, has to be interpreted with caution.
As the authors stated, the median CPAP level was
8 cmH2O for infants who developed a pneumothorax as
well as for those in whom a pneumothorax did not
occur. If the CPAP pressure would have been the cause
for the development of pneumothorax, it is interesting
that the incidence of air leaks was lower in the intub-
ation group, where infants were exposed to higher peak
and mean airway pressures as compared to the CPAP
group. A more reasonable explanation of these findings
might be the lower rate of infants treated with surfactant
in the CPAP-group and the high FiO2 intervention
threshold for intubation and surfactant administration
(FiO2 > 0.6), since surfactant treatment has been proven
to reduce the incidence of air leaks in preterm infants
[21]. The SUPPORT and CURPAP study with a similar
study design and similar PEEP levels of 5–8 cmH2O did
not find any difference in the incidence of air leaks, but
had a lower threshold (i.e., FiO2 > 0.4) for surfactant ad-
ministration [6, 7]. To our surprise, no clinical trial since
the introduction of nasal CPAP was conducted that
assessed the efficacy of different PEEP levels during nasal
CPAP treatment for RDS in the preterm population.
Given the facts that the available strategies to avoid
mechanical ventilation did not (yet) result in a reduction
of BPD and are still associated with high treatment fail-
ure rates and that other promising strategies (i.e., cell
based therapies) have to be critically evaluated before
introduction into clinical practice, it seems conclusive to
improve the effectiveness of the well-established CPAP
therapy as the currently accepted gold standard of non-
invasive respiratory support in VLBWI [28, 29]. Our hy-
pothesis is that the early application of a higher (6–8
cmH2O) versus a lower (3–5 cmH2O) PEEP range will
more effectively recruit and maintain lung volumes in
preterm infants with GA 26 + 0–29 + 6 weeks during the
first 120 h of life and further reduce the need for mech-
anical ventilation and respiratory failure. To avoid ex-
posure to unnecessary high continuous distending
pressures, we further decided to follow the approach of
titrating the level of PEEP within the randomized range
according to the fraction of inspired oxygen to maintain
arterial oxygen saturation in the target SpO2 range.
There are potential limitations in our study design that
we addressed in the pre-study meetings: (1) all partici-
pating centers use nasal CPAP and NIPPV as primary
respiratory support and post extubation. Because set-
tings (inspiratory time, peak inspiratory pressure and re-
spiratory rate) during NIPPV significantly affect the
applied mean airway pressure and gas exchange, this
could potentially result in unexpected and undesired dif-
ferences in the study outcomes if this strategy is used
unevenly between the two treatment groups. To resolve
this issue, we decided that settings and weaning during
the study intervention must be equally applied to both
treatment arms in terms of inspiratory times, respiratory
rate, and peak inspiratory pressures, which will be moni-
tored and documented during the study intervention.
The preparation of a center-specific protocol for the use
of NIPPV prior to study initiation is strongly recom-
mended and communicated during the pre-study meet-
ing. (2) Analysis of the pre-study surveillance protocol
revealed that participating centers use different modes of
surfactant administration (INSURE or less invasive sur-
factant administration) as well as different thresholds
and indications (FiO2, pCO2, work of breathing) for sur-
factant administration. However, participating centers
follow local guidelines ensuring that the indications and
the mode of surfactant application are used similar be-
tween the two study groups within each center. (3) One
of the primary endpoints is defined as need for intub-
ation and invasive mechanical ventilation > 1 h. Al-
though we strongly recommend that infants should be
intubated if FiO2 ≥ 0.5 for > 1 h and/or pCO2 ≥ 70
mmHg in two consecutive blood gas analysis > 2 h apart
after the application of a maximum of 2 surfactant
doses, some physicians may however withheld intubation
for any reasons. Therefore, we have chosen the criteria
FiO2 ≥ 0.5 for > 1 h and/or pCO2 ≥ 70 mmHg in two
consecutive blood gas analysis > 2 h apart after the appli-
cation of a maximum of 2 surfactant doses as fulfillment
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of the primary endpoint as well (treatment failure). The
abovementioned indicators for intubation (FiO2, pCO2)
will be documented on an hourly basis. (4) Some physi-
cians may have reservations against very high or very
low PEEP settings that may lead to protocol violations.
During the study preparation process and the pre-study
meetings, there was a high agreement between the par-
ticipating centers for the use of the two defined PEEP
ranges. The ventilator parameters PEEP and FiO2 are re-
corded on an hourly basis to confirm protocol compli-
ance or detect violence regarding the intended PEEP
settings, which will then be discussed with the study
monitor and the responsible investigator at the study site
as soon as possible.
Trial status
The start of recruitment is expected to be May 01, 2020.
The estimated date of completed recruitment is July 31,
2022. The protocol version number is 1.2. The date of
the protocol version is December 04, 2019.
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